Skip to main content
. Author manuscript; available in PMC: 2009 Nov 5.
Published in final edited form as: J Natl Cancer Inst. 2008 Oct 28;100(21):1500–1510. doi: 10.1093/jnci/djn351

Figure 2.

Figure 2

Activity of temozolomide and topotecan in human tumor xenografts. A) A375 melanoma xenografts. B) Colo 829 melanoma xenografts. Cells of both lines were implanted subcutaneously in female athymic nude (nu/nu NCr) mice (Animal Production Program, NCI-Frederick). Treatment was initiated when the tumors reached 150 mg. Temozolomide was administered by oral gavage as a single dose of 400 mg/kg or as three 200 mg/kg doses given 4 days apart (temozolomide 200 mg/kg × 3) (n=10 mice/dose group). Topotecan was administered intraperitoneally at 1 mg/kg 5 days per week for 2 weeks (n=10). The vehicle control group (n=20) was treated with three doses of saline given 4 days apart. Individual tumor weights were calculated as weight in mg = [length × width2]/2. Data are plotted as median tumor weights +/− 95% confidence intervals.